- Issuer ticker
-
VRTX
- Reported as of
-
23 Feb 2024
- Net transaction value
-
-$2,344,892
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
27 Feb 2024, 16:59:03 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Christiana Stevenson, Attorney-in-Fact
Key filing fact
Amit Sachdev filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 27 Feb 2024.
Key facts
- This page summarizes Amit Sachdev's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2024, 16:59.
Change
- Previous filing in this sequence was filed on 23 Feb 2024.
- Current net transaction value: -$2,344,892.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Tax liability
- Transaction value
- $1,066,090
- Shares
- -2,469
- Change %
- -4.1%
- Price
-
$431.79
- Shares after
- 58,329
- Date
- 23 Feb 2024
- Ownership
- Direct
VRTX
transaction
Common Stock
Sale
- Transaction value
- $1,278,803
- Shares
- -3,004
- Change %
- -5.2%
- Price
-
$425.70
- Shares after
- 55,325
- Date
- 26 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
-
- Shares after
- 882
- Date
- 23 Feb 2024
- Ownership
- 401(k)
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
-
- Shares after
- 6,565
- Date
- 23 Feb 2024
- Ownership
- Held in Trust
* marks a reported price that did not pass the local price check.
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses
1 footnote